AI Article Synopsis
Article Abstract
Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma. Pulmonary toxicity with thalidomide is a recognized potential complication; however, there have only been two case reports in the literature of lenalidomide-associated pulmonary toxicity. In this case, we describe a patient who developed profound dyspnea, decreased exercisetolerance, and new ground-glass opacities with reticulation, consistent with a nonspecific interstitial pneumonia pattern. Clinical suspicion for pulmonary drug toxicity was high and lenalidomide was discontinued. Within 2 weeks of stopping lenalidomide, the patient had significant improvement in dyspnea and interstitial changes on CT were resolving. After 8 weeks, there was complete resolution of symptoms. Lenalidomide-induced pulmonary toxicity is significantly debilitating but, to date, it appears to be reversible with discontinuation of the medication.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1078155211408374 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anemonin suppresses sepsis-induced acute lung injury by inactivation of nuclear factor-kappa B and activation of nuclear factor erythroid 2-related factor-2/heme oxygenase-1 pathway.
FASEB J
January 2025
Department of Cardiovascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Sepsis-induced acute lung injury (ALI) is a common acute and severe reason of death in the intensive care unit. Although the pathogenesis is complicated and multifactorial, elevated inflammation and oxidative stress are considered as fundamental mechanisms for the progression of ALI. Anemonin is a natural compound with diverse biological properties including anti-inflammatory and anti-oxidative effects.
View Article and Find Full Text PDFAssociation of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081.
Clin Lung Cancer
December 2024
Indiana University Simon Cancer Center, Indianapolis, IN. Electronic address:
Background: Immunotherapy has been widely incorporated into the treatment of patients with non-small-cell lung cancer (NSCLC). Many of these patients will experience immune-related adverse events (irAEs) without decreased efficacy. We report a retrospective analysis of the association between irAEs and efficacy outcomes from the BTCRC LUN 16-081 randomized phase 2 trial of consolidation nivolumab (N) plus ipilimumab (IPI) vs N alone following chemoradiotherapy in unresectable Stage IIIA/IIIB NSCLC.
View Article and Find Full Text PDFDiscovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.
J Med Chem
January 2025
Scorpion Therapeutics, 1 Winthrop Square, Boston, Massachusetts 02110, United States.
After L858R and ex19del epidermal growth factor receptor (EGFR) mutations, ex20ins mutations are the third most common class of driver-mutations in non-small cell lung cancer (NSCLC). Unfortunately, first-, second-, and third-generation EGFR tyrosine kinase inhibitors (TKIs) are generally ineffective for ex20ins patients due to insufficient mutant activity and selectivity over wild-type EGFR, leading to dose-limiting toxicities. While significant advances in recent years have been made toward identifying potent EGFR ex20ins mutant inhibitors, mutant vs wild-type EGFR selectivity remains a significant challenge.
View Article and Find Full Text PDFDynamic non-coding RNA biomarker reveals lung injury and repair induced by polystyrene nanoplastics.
Environ Int
January 2025
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, 210009, China.
Polystyrene nanoplastics (PS-NPs) are omnipresent in the air and can be inhaled by humans. However, their long-term adverse implications and toxicological mechanisms for human respiratory health are unclear. Therefore, this study aims to provide new insights into the pulmonary toxicity of PS-NPs using mice and organoid models.
View Article and Find Full Text PDFGasification-MILD combustion technology with ash-sludge recirculation for reducing multi-phase net dioxin discharges from a waste incineration.
Waste Manag
January 2025
School of Mechanical Engineering, Beijing Institute of Technology, Beijing 100081 China.
This study addresses the challenge of reducing "net" toxic pollutant discharge, specifically dibenzo-p-dioxins and dibenzofurans (PCDD/Fs), while minimizing the energy consumption and costs associated with detoxification. Our research focuses on reintroducing fly ash and scrubber sludge (ASR) into a hazardous waste thermal treatment system equipped with gasification-intense low oxygen dilution (GASMILD) and an advanced air pollution control system (APCS). This approach yielded a remarkable PCDD/F removal efficiency exceeding 99.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!